You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

375 Results
Drug
Other Name(s): Vectibix®
Jan 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia, according to specific clinical criteria
Updated
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), according to specific clinical criteria
Updated
Dec 2025
Drug
Other Name(s): Iclusig®
Updated
Dec 2025
Statistical Reports
Ontario Cancer Statistics 2024 is the fifth in a series of reports that provide comprehensive information on the burden of cancer in Ontario....
Feb 2025
Statistical Reports
Les statistiques sur le cancer en Ontario 2024 représentent le cinquième d'une série de rapports qui fournissent des informations approfondies sur l'...
Feb 2025
Drug
Other Name(s): Afinitor®
Updated
Dec 2025
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Updated
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Updated
Dec 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
ODB - General Benefit
    exemestane
Updated
Dec 2025
Regimen
Cancer Type:
Lung, 
Neuroendocrine (Lung)
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Updated
Dec 2025
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
ODB - General Benefit
    everolimus
Updated
Dec 2025

Pages